| CAS NO: | 607742-69-8 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 5mg | 电议 |
| 25mg | 电议 |
| Cas No. | 607742-69-8 |
| 别名 | 3-苯基磺酰基-8-(哌嗪-1-基)喹啉,SB-742457; GSK-742457; RVT-101 |
| 化学名 | 3-(benzenesulfonyl)-8-piperazin-1-ylquinoline |
| Canonical SMILES | C1CN(CCN1)C2=CC=CC3=CC(=CN=C32)S(=O)(=O)C4=CC=CC=C4 |
| 分子式 | C19H19N3O2S |
| 分子量 | 353.44 |
| 溶解度 | ≥ 17.65mg/mL in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | SB742457 is a selective antagonist of 5-HT6 receptor with a pKi value of 9.63 [1]. SB742457 has been found to be a highly selective 5-HT6 receptor antagonist with high affinity to human 5-HT6 receptor. The pKi value of SB742457 is 9.63. In addition, because of the orally bioavailable, SB742457 has been reported to promote brain penetration in rat over previously developed compounds. Besides, subchronic daily oral pre-dosing of SB742457 (1.5mg/kg) has been noted to significantly induce by the cholinergic antagonist scopolamine (0.5mg/kg) in a novel object recognition paradigm. Apart from these, acute oral treatment of SB742457 has been found to induce significant increases levels of glutamate and acetylcholine in extracellular in the medial prefrontal cortex of freely moving rats [1]. Reference: |
m.cnreagent.com